Healthcare >> CEO Interviews >> May 3, 2004
CLAYTON I. DUNCAN has been President, Chief Executive Officer and a
Director of Incara Pharmaceuticals Corporation since January 1995. From
1989 until 1994, Mr. Duncan was President and Chief Executive Officer of
Sphinx Pharmaceuticals Corporation, a biopharmaceutical company which
was acquired by Eli Lilly and Company in September 1994. From 1987 to
1989, Mr. Duncan was a Founder and Chairman of the Board of CRX Medical,
Inc., a predecessor to Closure Medical, Inc., a publicly traded medical
products company that markets products and conducts research and
development in the use of cyanoacrylates for wound management. Mr.
Duncan also serves on the Board of Carolina Ballet, a professional
ballet company located in the Research Triangle of North Carolina. He
received a Master's degree in English from the University of California
at Santa Barbara and an AB and MBA from the University of North Carolina
at Chapel Hill. Profile
Mr. Duncan: Incara is a development stage biopharmaceutical company
focused on a new class of small molecules. These compounds are
